Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment

Abstract

Introduction Vestibular schwannomas (VS) are histologically benign tumors arising from cranial nerve VIII. Far from a homogenous proliferation of Schwann cells, mounting evidence has highlighted the complex nature of the inflammatory microenvironment in these tumors.

Methods A review of the literature pertaining to inflammation, inflammatory molecular pathways, and immune-related therapeutic targets in VS was performed. Relevant studies published up to June 2020 were identified based on a literature search in the PubMed and MEDLINE databases and the findings were synthesized into a concise narrative review of the topic.

Results The VS microenvironment is characterized by a dense infiltrate of inflammatory cells, particularly macrophages. Significantly higher levels of immune cell infiltration are observed in growing versus static tumors, and there is a demonstrable interplay between inflammation and angiogenesis in growing VS. While further mechanistic studies are required to ascertain the exact role of inflammation in angiogenesis, tumor growth, and Schwann cell control, we are beginning to understand the key molecular pathways driving this inflammatory microenvironment, and how these processes can be monitored and targeted in vivo.

Conclusion Observational research has revealed a complex and heterogeneous tumor microenvironment in VS. The functional landscape and roles of macrophages and other immune cells in the VS inflammatory infiltrate are, however, yet to be established. The antiangiogenic drug bevacizumab has shown the efficacy of targeted molecular therapies in VS and there is hope that agents targeting another major component of the VS microenvironment, inflammation, will also find a place in their future management.

Keywords

vestibular schwannoma - inflammation - tumor-associated macrophages - tumor immunology - immunotherapy - immunomodulation - angiogenesis - antiangiogenic - bevacizumab - biomarkers

Note

Aspects of this work were presented at the British Skull Base Society Meetings in January 2019 in Glasgow, UK, and January 2020 in London, UK. Further presentations were made at the Society of British Neurological Surgeons Meeting in March 2019 in Manchester, UK.

^* Contributed equally and share first authorship.

Publikationsverlauf

Eingereicht: 19. Juni 2020

Angenommen: 25. Juli 2020

Artikel online veröffentlicht:
10. September 2020

• References

• 1 Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005; 26 (01) 93-97
• 2 Halliday D, Parry A, Evans DG. Neurofibromatosis type 2 and related disorders. Curr Opin Oncol 2019; 31 (06) 562-567
• 3 Pathmanaban ON, Sadler KV, Kamaly-Asl ID. et al. Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. JAMA Neurol 2017; 74 (09) 1123-1129
• 4 Lees KA, Tombers NM, Link MJ. et al. Natural history of sporadic vestibular schwannoma: a volumetric study of tumor growth. Otolaryngol Head Neck Surg 2018; 159 (03) 535-542
• 5 Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The natural history of vestibular schwannoma. Otol Neurotol 2006; 27 (04) 547-552
• 6 Lewis D, Donofrio CA, O'Leary C. et al. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. J Neurosurg 2020; 29: 1-11
• 7 de Vries M, Hogendoorn PC, Briaire-de Bruyn I, Malessy MJ, van der Mey AG. Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch 2012; 460 (06) 629-636
• 8 Labit-Bouvier C, Crebassa B, Bouvier C, Andrac-Meyer L, Magnan J, Charpin C. Clinicopathologic growth factors in vestibular schwannomas: a morphological and immunohistochemical study of 69 tumours. Acta Otolaryngol 2000; 120 (08) 950-954
• 9 Hannan CJ, Lewis D, O'Leary C. et al. The inflammatory microenvironment in vestibular schwannoma. Neuro Oncol Adv 2020; 2 (01) 1-12
• 10 de Vries M, Briaire-de Bruijn I, Malessy MJ, de Bruïne SF, van der Mey AG, Hogendoorn PC. Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 2013; 34 (02) 347-352
• 11 Antoni NRE. Über Rückenmarkstumoren und Neurofibrome. Munich: JF Bergmann; 1920
• 12 Escalona-Zapata J, Diez Nau MD. The nature of macrophages (foam cells) in neurinomas. Tissue culture study. Acta Neuropathol 1978; 44 (01) 71-75
• 13 Bedavanija A, Brieger J, Lehr H-A, Maurer J, Mann WJ. Association of proliferative activity and size in acoustic neuroma: implications for timing of surgery. J Neurosurg 2003; 98 (04) 807-811
• 14 Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454 (7203): 436-444
• 15 Zhang SC, Hu ZQ, Long JH. et al. Clinical implications of tumor-infiltrating immune cells in breast cancer. J Cancer 2019; 10 (24) 6175-6184
• 16 Di Caro G, Cortese N, Castino GF. et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 2016; 65 (10) 1710-1720
• 17 Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2016; 19 (01) 20-27
• 18 Vidyarthi A, Agnihotri T, Khan N. et al. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. Cancer Immunol Immunother 2019; 68 (12) 1995-2004
• 19 Proctor DT, Huang J, Lama S, Albakr A, Van Marle G, Sutherland GR. Tumor-associated macrophage infiltration in meningioma. Neuro Oncol Adv 2019; 1 (01) 1-10
• 20 Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176 (01) 287-292
• 21 Domingues PH, Teodósio C, Ortiz J. et al. Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol 2012; 181 (05) 1749-1761
• 22 Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164 (12) 6166-6173
• 23 Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5 (12) 953-964
• 24 Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23 (11) 549-555
• 25 Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008; 112 (04) 935-945
• 26 Mantovani A. Reflections on immunological nomenclature: in praise of imperfection. Nat Immunol 2016; 17 (03) 215-216
• 27 Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009; 33 (01) 118-126
• 28 Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009; 59 (05) 300-305
• 29 Tamura R, Morimoto Y, Sato M. et al. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas. J Neurooncol 2020; 146 (02) 265-273
• 30 Perry A, Graffeo CS, Carlstrom LP. et al. Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma. J Neurosurg 2019; 1-9
• 31 Rasmussen N, Bendtzen K, Thomsen J, Tos M. Specific cellular immunity in acoustic neuroma patients. Otolaryngol Head Neck Surg 1983; 91 (05) 532-536
• 32 Taurone S, Bianchi E, Attanasio G. et al. Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue. Mol Med Rep 2015; 12 (01) 737-745
• 33 Breun M, Schwerdtfeger A, Martellotta DD. et al. CXCR4: A new player in vestibular schwannoma pathogenesis. Oncotarget 2018; 9 (11) 9940-9950
• 34 Dilwali S, Landegger LD, Soares VYR, Deschler DG, Stankovic KM. Secreted factors from human vestibular schwannomas can cause cochlear damage. Sci Rep 2015; 5: 18599-18599
• 35 Dilwali S, Briët MC, Kao S-Y. et al. Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth. Mol Oncol 2015; 9 (07) 1359-1370
• 36 Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 2018; 18 (05) 309-324
• 37 Ammoun S, Provenzano L, Zhou L. et al. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 2014; 33 (03) 336-346
• 38 Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18 (55) 7908-7916
• 39 Behling F, Ries V, Skardelly M. et al. COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake. Acta Neuropathol Commun 2019; 7 (01) 105
• 40 Kang HC, Kim IH, Park CI, Park SH. Immunohistochemical analysis of cyclooxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: correlation with tumor grade and clinical outcome after radiotherapy. Neuropathology 2014; 34 (05) 446-454
• 41 Dilwali S, Kao S-Y, Fujita T, Landegger LD, Stankovic KM. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl Res 2015; 166 (01) 1-11
• 42 Aoki T, Frȍsen J, Fukuda M. et al. Prostaglandin E2-EP2-NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms. Sci Signal 2017; 10 (465) eaah6037
• 43 Lewis D, Roncaroli F, Agushi E. et al. Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro-oncol 2019; 21 (03) 314-325
• 44 Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; 14 (07) 399-416
• 45 Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86 (05) 1065-1073
• 46 Cayé-Thomasen P, Werther K, Nalla A. et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005; 26 (01) 98-101
• 47 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9 (06) 669-676
• 48 Freire Valls A, Knipper K, Giannakouri E. et al. VEGFR1⁺ metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal cancer patient outcome. Clin Cancer Res 2019; 25 (18) 5674-5685
• 49 Kerber M, Reiss Y, Wickersheim A. et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008; 68 (18) 7342-7351
• 50 Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87 (08) 3336-3343
• 51 Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest 2016; 126 (10) 3672-3679
• 52 Li K-L, Djoukhadar I, Zhu X. et al. Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro-oncol 2016; 18 (02) 275-282
• 53 Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 2019; 16 (06) 356-371
• 54 Haworth KB, Arnold MA, Pierson CR. et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget 2017; 8 (47) 82037-82048
• 55 Tamura R, Fujioka M, Morimoto Y. et al. A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun 2019; 10 (01) 5758
• 56 Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol 2018; 71 (03) 189-194
• 57 Wang S, Liechty B, Patel S. et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 2018; 138 (01) 183-190
• 58 Archibald DJ, Neff BA, Voss SG. et al. B7-H1 expression in vestibular schwannomas. Otol Neurotol 2010; 31 (06) 991-997
• 59 Blakeley JO, Evans DG, Adler J. et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2012; 158A (01) 24-41
• 60 Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. Glia 2013; 61 (01) 10-23
• 61 Serkova NJ. Nanoparticle-based magnetic resonance imaging on tumor-associated macrophages and inflammation. Front Immunol 2017; 8: 590
• 62 Grimes N, Hannan C, Tyson M, Thwaini A. The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma. Can Urol Assoc J 2018; 12 (07) E345-E348
• 63 Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open 2020; 10 (06) e035031
• 64 Li MX, Liu XM, Zhang XF. et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 2014; 134 (10) 2403-2413
• 65 Templeton AJ, McNamara MG, Šeruga B. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106 (06) dju124
• 66 Bambury RM, Teo MY, Power DG. et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 2013; 114 (01) 149-154
• 67 Kontorinis G, Crowther JA, Iliodromiti S, Taylor WA, Locke R. Neutrophil to lymphocyte ratio as a predictive marker of vestibular schwannoma growth. Otol Neurotol 2016; 37 (05) 580-585
• 68 Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185 (04) 2273-2284
• 69 Kandathil CK, Cunnane ME, McKenna MJ, Curtin HD, Stankovic KM. Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis. Otol Neurotol 2016; 37 (09) 1428-1434
• 70 MacKeith S, Wasson J, Baker C. et al. Aspirin does not prevent growth of vestibular schwannomas: a case-control study. Laryngoscope 2018; 128 (09) 2139-2144
• 71 Rolny C, Mazzone M, Tugues S. et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011; 19 (01) 31-44
• 72 Hagemann T, Lawrence T, McNeish I. et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205 (06) 1261-1268
• 73 Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119 (03) 651-665
• 74 Hamid O, Robert C, Daud A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369 (02) 134-144
• 75 Zhao J, Chen AX, Gartrell RD. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 2019; 25 (03) 462-469
• 76 Tamura R, Tanaka T, Ohara K. et al. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci 2019; 110 (02) 499-508
• 77 Hodi FS, Lawrence D, Lezcano C. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2 (07) 632-642
• 78 Rini BI, Plimack ER, Stus V. et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380 (12) 1116-1127